{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-23-000083","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.342721+00:00","generated_at":"2026-06-08T21:46:38.792925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics Q3 revenue $191.9M, up 23% YoY; raises FY2023 guidance, introduces FY2024 guidance","bullets":["Q3 revenue $191.9M (+23% YoY); GAAP EPS -$0.75, adjusted EPS -$0.03.","Testing volume ex-SneakPeek +18% YoY; hereditary cancer +18%, prenatal +20%, GeneSight +19%.","Raised FY2023 revenue guidance to $747-753M (prev $730-750M); introduced FY2024 guidance $815-835M.","Settled Ravgen litigation for $12.75M plus contingent $21.25M; expanded credit facility to $115M.","New UnitedHealthcare contract effective Jan 1, 2024 through 2027; appointed Sam Raha COO effective Dec 11."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-23-000083","json":"https://secwatch.observer/filing/0000899923-23-000083.json","markdown":"https://secwatch.observer/filing/0000899923-23-000083.md","text":"https://secwatch.observer/filing/0000899923-23-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/0000899923-23-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/mygn-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:46:38.792925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c1214b6f22c7d7b2bc7663cf6a294e2f1782e0e","claim":"MYRIAD GENETICS INC reported three months ended September 30, 2023 results: revenue $191.9 million, EPS $(0.75). Guidance raised.","evidence_excerpt":"respectively. ▪ Prenatal test volumes grew 20% and 14% year-over-year, respectively, excluding contributions from the SneakPeek Early Gender DNA Test. • Third quarter revenue of $191.9 million, grew 23% year-over-year, inclusive of a $7.1 million change of estimate 1 in the current quarter versus $(5.3) million change of estimate 1 in the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/0000899923-23-000083-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$191.9 million"},{"label":"EPS","value":"$(0.75)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}